Trial intelligence / Profile preview

DISCERN: Dual vs Single Checkpoint Inhibition in PDL-1 Negative NSCLC

NCT06364917Phase 2Recruiting

Sponsor: University of Alabama at Birmingham
Start: May 2025
Primary completion: Apr 2027
Modality: Monoclonal Antibodies
Countries: 1

Overview

Phase 2, randomised, open-label trial of nivolumab, ipilimumab and pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Rate of Molecular Response at 64 days. Started May 2025; status: recruiting.

Drugs

nivolumabipilimumabpembrolizumab

Conditions

non-small cell lung cancer (NSCLC)

Beyond the preview

Go deeper on NCT06364917.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06364917.